Please Wait
Applying Filters...
menu
    • menu
    DMF filings hit all-time high in Q3 2024; China tops list with 58% increase in Type II submissions

    Data Compilation
    #PharmaFlow

    Pipeline Prospector Sept 2024: BMS wins landmark FDA approval for schizophrenia med; Sanofi’s Dupixent okayed for COPD

    Stock Recap
    #PipelineProspector

    Menu

    Dihydroergocristine

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls download

    Filters

    clear-filterReset all filters
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    Data in the table can be downloaded after upgrading. In the meantime, you can access the data through the menu.

    Last Updated on PharmaCompass Virtual Booth Country Certificate Holder Certificate No. Substance Issue Date Status Type End Date Substance No.
    28/10/2024 Curia
    U.S.A
    		 CURIA ITALY S.R.L. Rozzano, Milano IT R1-CEP 2000-073 - Rev 07 Dihydroergocristine mesilate 2023-03-14 Valid Chemical 1416
    28/10/2024 Teva API
    Israel
    		 TEVA CZECH INDUSTRIES S.R.O. Opava CZ R1-CEP 2001-381 - Rev 03 Dihydroergocristine mesilate 2012-08-02 Withdrawn by Holder Chemical 2023-05-04 1416